ERBB2 and breast carcinoma: Breast cancer represents an interesting pathological setting where CDKis constitute a current therapeutic tool and also provide the most advanced perspectives, especially in advanced hormone receptor (HR)-positive (estrogen receptor-positive and/or progesterone receptor-positive) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer [2,4,5].